Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Non-Current Assets (2021 - 2025)

Bioregenx has reported Non-Current Assets over the past 5 years, most recently at $159721.0 for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 20.43% year-over-year to $159721.0; the TTM value through Dec 2025 reached $2.1 million, down 95.95%, while the annual FY2025 figure was $159721.0, 20.43% down from the prior year.
  • Non-Current Assets for Q4 2025 was $159721.0 at Bioregenx, down from $894608.0 in the prior quarter.
  • Over five years, Non-Current Assets peaked at $18.1 million in Q1 2024 and troughed at $31640.0 in Q4 2023.
  • A 5-year average of $4.0 million and a median of $174041.5 in 2025 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: soared 51040.25% in 2024 and later tumbled 98.96% in 2025.
  • Year by year, Non-Current Assets stood at $103404.0 in 2021, then crashed by 43.45% to $58473.0 in 2022, then tumbled by 45.89% to $31640.0 in 2023, then surged by 534.45% to $200739.0 in 2024, then dropped by 20.43% to $159721.0 in 2025.
  • Business Quant data shows Non-Current Assets for BRGX at $159721.0 in Q4 2025, $894608.0 in Q3 2025, and $900985.0 in Q2 2025.